FDA said on April 16 that it is revoking the emergency use authorization (EUA) for bamlanivimab—when administered alone—to be used for treatment of mild to moderate COVID-19 in adults and certain pediatric patients. 

More than 87,000 Americans died from drug overdoses in the 12-month period that ended in September 2020, according to preliminary CDC data, which indicate that the U.S. drug overdose mortality rate increased last year.

Patients will be coming to pharmacists with questions and concerns as the recommendation to suspend use of the Janssen (Johnson & Johnson, J&J) vaccine remains in place.